Dermata Therapeutics, Inc. (DRMAW) — 8-K Filings

8-K Filings (28)

• Dermata Therapeutics Files 8-K: Material Agreement & Equity Sales — Dec 29, 2025 Risk: medium
  Dermata Therapeutics, Inc. announced on December 23, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales
• Dermata Therapeutics Terminates Material Agreement — Nov 18, 2025 Risk: medium
  Dermata Therapeutics, Inc. announced the termination of a material definitive agreement on November 17, 2025. The company, incorporated in Delaware with its pri
• 8-K Filing — Nov 7, 2025
• Dermata Therapeutics Files 8-K — Sep 17, 2025 Risk: medium
  Dermata Therapeutics, Inc. filed an 8-K on September 17, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these
• Dermata Therapeutics Files 8-K: Other Events Reported — Sep 10, 2025 Risk: medium
  Dermata Therapeutics, Inc. filed an 8-K on September 10, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these
• Dermata Therapeutics to be Acquired by 03 Life Sciences — Aug 25, 2025 Risk: medium
  Dermata Therapeutics, Inc. announced on August 22, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is
• Dermata Therapeutics Files 8-K on Security Holder Rights — Jul 30, 2025 Risk: medium
  On July 30, 2025, Dermata Therapeutics, Inc. filed an 8-K report detailing material modifications to the rights of security holders and amendments to its articl
• Dermata Therapeutics Files 8-K on Security Holder Vote — Jul 16, 2025 Risk: low
  On July 15, 2025, Dermata Therapeutics, Inc. filed an 8-K report indicating that it submitted matters to a vote of its security holders. The filing does not spe
• Dermata Therapeutics Faces Delisting Concerns — Jul 7, 2025 Risk: high
  Dermata Therapeutics, Inc. filed an 8-K on July 7, 2025, reporting a notice of delisting or failure to meet continued listing standards as of July 2, 2025. The
• Dermata Therapeutics Files 8-K: Accountant Change — Jun 5, 2025 Risk: medium
  Dermata Therapeutics, Inc. filed an 8-K on June 5, 2025, reporting changes in its certifying accountant. The company, incorporated in Delaware, is involved in p
• Dermata Therapeutics Files 8-K — May 21, 2025 Risk: medium
  Dermata Therapeutics, Inc. filed an 8-K on May 21, 2025, reporting events on May 20, 2025. The filing indicates a Regulation FD Disclosure and other events, but
• Dermata Therapeutics Faces Delisting Concerns — May 16, 2025 Risk: high
  Dermata Therapeutics, Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to meet continued listing standards as of May 14, 2025. The
• Dermata Therapeutics Files 8-K — Apr 15, 2025 Risk: low
  Dermata Therapeutics, Inc. filed an 8-K on April 15, 2025, reporting on various events. The filing includes information related to financial statements and exhi
• Dermata Therapeutics Files 8-K: Material Agreements & Equity Sales — Mar 28, 2025 Risk: medium
  Dermata Therapeutics, Inc. announced on March 27, 2025, that it entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of
• Dermata Therapeutics Files 8-K Report — Mar 27, 2025 Risk: low
  On March 27, 2025, Dermata Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
• Dermata Therapeutics Faces Delisting Notice — Mar 25, 2025 Risk: high
  Dermata Therapeutics, Inc. filed an 8-K on March 25, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based
• Dermata Therapeutics Files 8-K: Material Agreement & Equity Sales — Jan 23, 2025 Risk: medium
  Dermata Therapeutics, Inc. announced on January 21, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales
• Dermata Therapeutics Files 8-K for Material Agreement — Jan 21, 2025 Risk: medium
  Dermata Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting a material definitive agreement entered into on January 17, 2025. The filing also include
• Dermata Therapeutics Files 8-K on Financials — Nov 14, 2024 Risk: low
  Dermata Therapeutics, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition. The filing also includes Regulatio
• Dermata Therapeutics Files 8-K on Equity Sales — Sep 17, 2024 Risk: medium
  On September 16, 2024, Dermata Therapeutics, Inc. entered into a material definitive agreement related to the unregistered sale of equity securities. The compan
• Dermata Therapeutics Files 8-K — Aug 2, 2024 Risk: low
  Dermata Therapeutics, Inc. filed an 8-K on August 2, 2024, to report other events and financial statements. The filing does not contain specific details about t
• Dermata Therapeutics Enters Material Definitive Agreement — Jun 7, 2024 Risk: medium
  Dermata Therapeutics, Inc. announced on June 7, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details on the
• Dermata Therapeutics Secures $1.5M Private Placement — Jun 5, 2024 Risk: medium
  Dermata Therapeutics, Inc. announced on June 4, 2024, that it entered into a securities purchase agreement to sell approximately $1.5 million of its common stoc
• Dermata Therapeutics Faces Delisting Concerns — May 24, 2024 Risk: high
  Dermata Therapeutics, Inc. filed an 8-K on May 24, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of May 20
• Dermata Therapeutics Raises $1.5M via Stock and Warrant Sale — May 17, 2024 Risk: medium
  Dermata Therapeutics, Inc. announced on May 17, 2024, that it entered into a Securities Purchase Agreement and a Warrant Agreement. These agreements involve the
• Dermata Therapeutics Files 8-K for Corporate Updates — May 14, 2024 Risk: medium
  Dermata Therapeutics, Inc. filed an 8-K on May 14, 2024, reporting material modifications to the rights of security holders and amendments to its articles of in
• Dermata Therapeutics Appoints New Officers, Files 8-K — May 7, 2024 Risk: medium
  On May 7, 2024, Dermata Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the appointment of Dr. Michael A. Smith as Ch
• DRMA Files 8-K on Shareholder Vote Submission — Jan 12, 2024
  Dermata Therapeutics, Inc. (DRMA) filed an 8-K on January 12, 2024, to report that it submitted matters to a vote of its security holders. This filing indicates

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX